Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAC GUCY2C

Next Previous
X
Search
Drug Profile

TAC GUCY2C

Alternative Names: GUCY2C-TAC T; TAC-GUCY2C

Latest Information Update: 17 Nov 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Triumvira
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Colorectal cancer; Gastrointestinal cancer; Pancreatic cancer

Most Recent Events

  • 10 Nov 2022 Pharmacodynamics data from a preclinical study in Colorectal cancer released by Triumvira Immunologics
  • 14 Oct 2022 Triumvira announces intention to submit IND applications by late 2023 or early 2024 (Triumvira pipeline, October 2022)
  • 12 Oct 2022 Preclinical trials in Gastrointestinal cancer in USA (Parenteral) (Triumvira pipeline, October 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top